Robert W. Baird analyst Michael Polark maintained a Buy rating on Inspire Medical Systems (NYSE:INSP) Inc on Wednesday, setting a price target of $260, which is approximately 31.39% above the present share price of $197.88.
Polark expects Inspire Medical Systems Inc to post earnings per share (EPS) of -$0.28 for the second quarter of 2021.
The current consensus among 6 TipRanks analysts is for a Strong Buy rating of shares in Inspire Medical Systems, with an average price target of $260.25.
The analysts price targets range from a high of $266 to a low of $255.
In its latest earnings report, released on 12/31/2020, the company reported a quarterly revenue of $46.01 million and a net profit of -$7.06 million. The company's market cap is $5.52 billion.
According to TipRanks.com, Robert W. Baird analyst Michael Polark is currently ranked with 3 stars on a 0-5 stars ranking scale, with an average return of 9.1% and a 50.00% success rate.
Inspire Medical Systems, Inc. engages in the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea. It offers inspire therapy, which consists of a remote control and implantable components that includes pressure sensing lead, a neurostimulator, and a stimulation lead. The company was founded by Timothy P. Herbert in November 2007 and is headquartered in Golden Valley, MN.